1. Kim, Yona, You, Ji Hyeon, Ryu, Yeonjoo, Park, Sung-Hye, Paek, Sun Ha. 2024. ELAVL2 loss promotes aggressive mesenchymal transition in glioblastoma. In NPJ precision oncology, 8, 79. doi:10.1038/s41698-024-00566-1. https://pubmed.ncbi.nlm.nih.gov/38548861/
2. Berto, Stefano, Usui, Noriyoshi, Konopka, Genevieve, Fogel, Brent L. 2016. ELAVL2-regulated transcriptional and splicing networks in human neurons link neurodevelopment and autism. In Human molecular genetics, 25, 2451-2464. doi:. https://pubmed.ncbi.nlm.nih.gov/27260404/
3. Heddar, Abdelkader, Ogur, Cagri, Da Costa, Sabrina, Catteau-Jonard, Sophie, Misrahi, Micheline. 2022. Genetic landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized medicine. In EBioMedicine, 84, 104246. doi:10.1016/j.ebiom.2022.104246. https://pubmed.ncbi.nlm.nih.gov/36099812/
4. Chalupnikova, Katerina, Solc, Petr, Sulimenko, Vadym, Sedlacek, Radislav, Svoboda, Petr. 2014. An oocyte-specific ELAVL2 isoform is a translational repressor ablated from meiotically competent antral oocytes. In Cell cycle (Georgetown, Tex.), 13, 1187-200. doi:10.4161/cc.28107. https://pubmed.ncbi.nlm.nih.gov/24553115/